POMDOCTOR LIMITED Announces Receipt of Nasdaq Notice
Get Alerts POM Hot Sheet
Join SI Premium – FREE
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until
In the event the Company does not regain compliance by
The Deficiency Letter will have no effect on the Company's business operations, and the Company will take all reasonable measures to regain compliance.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: [email protected]
Ascent Investor Relations LLC
Phone: +1-646-932-7242
Email: [email protected]
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-receipt-of-nasdaq-notice-302674985.html
SOURCE POMDOCTOR LIMITED
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
- Astrana Health names two executives to expand leadership team
- Beam Global reports Q2 2026 revenue above $8.5M, up 170% from Q1
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share